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Liver steatosisThe isoleucine tomethionine substitution at position 148 in the patatin-like phospholipase domain containing 3
protein (PNPLA3; I148M variant, rs738409) is associated with liver fat accumulation and an increased risk of
chronic liver disease ranging fromhepatitis to hepatocellular carcinoma. This reviewdiscusses the interaction be-
tween the PNPLA3 I148Mvariant and obesity/intake of speciﬁc nutrients in determining the susceptibility to liver
disease.Wepresent the results of several studies showing that obesity or alcohol abuse enhances the effect of the
PNPLA3 I148M variant on the liver.We also show that speciﬁc nutrients interact with the PNPLA3 I148M variant
in modulating liver disease susceptibility.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The accumulation of fat in the liver is a pathologic condition also
known as hepatic steatosis. Hepatic steatosis is the most common
chronic liver disorder in Western countries affecting up to one third of
the population in the United States of America (Browning,
Szczepaniak, Dobbins, Nuremberg, Horton, Cohen, et al., 2004). In
some individuals, hepatic steatosis is associated with liver inﬂamma-
tion, whichmay progress to more serious liver disorders such as cirrho-
sis and hepatocellular carcinoma (HCC) (Adams, Lymp, St Sauver,
Sanderson, Lindor, Feldstein, et al., 2005).
In 2008, a genome-wide association study in a population compris-
ing Hispanic, African American and European American subjects
showed that a common genetic variant in the patatin-like phospholi-
pase domain containing 3 protein (PNPLA3) gene is associated with
liver fat accumulation (Romeo, Kozlitina, Xing, Pertsemlidis, Cox,
Pennacchio, et al., 2008). The substitution of isoleucine to methioninehysiology and Transplantation,
le Policlinico, Pad. Granelli, Via
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. This is an open access article underat position 148 (I148M, rs738409) in the PNPLA3 protein was the ﬁrst
variant robustly associated with an increased risk for hepatic steatosis.
Many other studies in different populations have since conﬁrmed this
association and shown an enrichment of the mutant PNPLA3 148M al-
lele in subjects with chronic liver disorders ranging from liver inﬂam-
mation to cirrhosis and HCC, suggesting that the allele may be
responsible for this progression (Corradini, Burza, Molinaro, & Romeo,
2011; Sookoian & Pirola, 2011; Valenti, Al-Serri, Daly, Galmozzi,
Rametta, Dongiovanni, et al., 2010).
Excess intake of calories (i.e. obesity), alcohol and speciﬁc nutrients
(e.g. fructose) are well-established risk factors for hepatic steatosis
(Becker, Deis, Sorensen, Gronbaek, BorchJohnsen, Muller, et al., 1996;
Bedogni, Miglioli, Masutti, Tiribelli, Marchesini & Bellentani, 2005;
Ouyang, Cirillo, Sautin, McCall, Bruchette, Diehl, et al., 2008). However,
the individual response to such stimuli is extremely variable (Daly,
Ballestri, Carulli, Loria, & Day, 2011). In this review, we examine the in-
terplay between the PNPLA3 148M variant and nutrients, which ex-
plains a proportion of the individual susceptibility to diet-induced
hepatic steatosis (Table 1) and represents a paradigm of nutrigenetics.
2. Obesity
Obesity is a major risk factor for hepatic steatosis and inﬂammation
(Anstee, Targher, & Day, 2013; Bedogni et al., 2005). In a cohort of 678
obese Italian individuals with a mean body-mass index of 41 kg/m2,
we tested the hypothesis that excess body weight would expose the as-
sociation of the PNPLA3 I148Mvariantwith liver damage and found that
carriers of the 148M allele had higher serum transaminase levelsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Risk factors interact with the PNPLA3 I148M variants in determining the risk for chronic liver disease.
Risk factor Outcome of risk factor — 148M PNPLA3 interaction
Obesity Higher serum transaminases, nonalcoholic liver disease, HCC
Alcohol Alcoholic liver disease, HCC
Carbohydrates Hepatic retention of newly synthesized triglycerides
Fatty acids Reduced amount of circulating oleic acid
Iron Higher serum transaminases and liver steatosis in subjects with hemochromatosis
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in serum transaminases is a common sign of hepatic steatosis, indicating
liver damage and release of liver enzymes into the blood (Amacher,
1998). The hypothesis that obesity enhances the effect of the PNPLA3
I148M variant on liver fat was subsequently supported by other studies
showing that obese carriers of the PNPLA3 variant are at higher risk of
developing hepatic steatosis (Petit, Guiu, Masson, Duvillard, Jooste,
Bufﬁer, et al., 2010; Valenti, Alisi, Galmozzi, Bartuli, Del Menico,
Alterio, et al., 2010). In a Chinese cohort with nonalcoholic
steatohepatitis, Li et al. showed that body-mass index interacts with
the PNPLA3 I148M variant to promote increased transaminase levels
(Li, Xing, Tian, & Ku, 2012), conﬁrming the interaction between the
PNPLA3 variant and the degree of obesity.
Long-term interaction between chronic stressors and genetic back-
ground may promote permanent damage and diseases. When obesity
develops during childhood, it is associated with future increased risk
of developing obesity-related comorbidities, including chronic liver dis-
ease (Berentzen, Gamborg, Holst, Sørensen, & Baker, 2013; Freedman,
Khan, Serdula, Dietz, Srinivasan&Berenson, 2004, 2005). Of note, in car-
riers of the 148M variant, an excess in adiposity in children determines
liver damage early in life (Lin, Chang, Hu, Yang, Chang & Ni, 2011;
Romeo et al., 2010; Santoro, Kursawe, D'Adamo, Dykas, Zhang, Bale,
et al., 2010), suggesting that obese young 148M carrierswill be exposed
to chronic liver damage throughout their lives.
Body fat distribution between the subcutaneous and visceral com-
partments is an important determinant of obesity metabolic complica-
tions including liver fat accumulation. Waist-to-hip ratio is commonly
used in clinical studies as a proxy for abdominal fat. A study in obese Ital-
ian children showed that the extent of the association between the
PNPLA3 I148M variant and liver damage depends on the abdominal fat
accumulation measured as waist-to-hip ratio (Miraglia Del Giudice,
Grandone, Cirillo, Santoro, Amato, Brienza, et al., 2011).Moreover, anoth-
er study performed in a European American population showed that vis-
ceral adipose tissue measured by computed tomography interacts with
the PNPLA3 I148M variant in determining liver fat accumulation (Graff,
North, Franceschini, Reiner, Feitosa, Carr, et al., 2013). Interestingly, the
interaction between abdominal fat and PNPLA3 I148M in the pathogene-
sis of fat accumulation has also been shown in an Italian cohort in a liver
disease of different etiology, namely chronic hepatitis C (Zampino,
Coppola, Cirillo, Boemio, Pisaturo, Marrone, et al., 2013).
Steatosis of the liver may progress to inﬂammation and ﬁbrosis with
profound disruption of the normal architecture and function of the liver
leading to cirrhosis. Results from a cohort of 266 Argentinean subjects
have shown that carriers of the 148M allele have higher risk of liver in-
ﬂammation evaluated by liver biopsy (Sookoian, Castaño, Burgueño,
Gianotti, Rosselli & Pirola, 2009). We also examined the hepatic conse-
quences of carrying the148Mallele in adults and childrenwithnonalco-
holic fatty liver.We showed that a greater steatosis severity and signs of
liver ﬁbrosis and inﬂammation were present in carriers of the 148M al-
lele (Valenti, Alisi, et al., 2010; Valenti, Al-Serri, et al., 2010).
From a clinical perspective, chronic liver damage may evolve into
HCC,which represents the end of the natural history of chronic liver dis-
ease. To examine the long-term effect of the interaction between obesi-
ty and the PNPLA3 I148Mvariant, we studied a cohort from the Swedish
Obese Subjects (SOS) study at a 15-year follow-up (Burza, Pirazzi,
Maglio, Sjöholm, Mancina, Svensson, et al., 2012). The cohortcomprised: 1754 individuals who had undergone bariatric surgery and
experienced subsequent sustainedweight loss and amelioration ofmet-
abolic parameters in the follow-up; and 1719 individuals who had not
undergone surgery and thus constituted the control group character-
ized by persistent morbid obesity. At the 15-year follow-up, 5 cases of
HCC were observed in the control group and 4 in the surgery group.
The PNPLA3 148M allele was associated with increased HCC risk only
in the SOS control group (hazard ratio 5.9; 95% conﬁdence interval
1.5–24; P value= 0.01). It is worth nothing that all the subjectswho de-
veloped HCC in the control group did not have other known risk factors
for liver disease and 4 of them did not have a diagnosis of cirrhosis.
Weight loss is known to reverse liver fat accumulation and thus prevent
the evolution to more serious liver disease. In the SOS surgery group,
weight loss suppressed the association between the I148M variant and
HCC risk (hazard ratio 1.2; 95% conﬁdence interval 0.2–6.3; P value =
0.80) (Burza et al., 2012). Moreover, we also showed that bariatric sur-
gery in obese adults abolishes the association of the PNPLA3 genetic var-
iant with liver damage (Palmer, Maglio, Pirazzi, Burza, Adiels, Burch,
et al., 2012). This is also supported by a greater liver fat reduction (mea-
sured by magnetic resonance imaging) after weight loss in individuals
homozygous for the 148Mallele compared to 148I homozygous subjects
(Sevastianova, Kotronen, Gastaldelli, Perttilä, Hakkarainen, Lundbom,
et al., 2011). This ﬁnding underlines the importance of the PNPLA3
I148M variant as a risk factor for liver disease in obese individuals.
In conclusion, excessive caloric intake resulting in obesity is a major
determinant of chronic liver disease particularly in carriers of the
PNPLA3 148M allele. Importantly, this association is reversible after
weight loss.
3. Alcohol intake
Alcohol intake is a well-established risk factor for chronic liver dis-
ease. The progression from alcoholic damage to hepatitis and ﬁbrosis
is mainly dependent on environmental factors (e.g. age at onset, dura-
tion of abuse, quantity of at-risk alcohol intake) and on genetic back-
ground (Bedogni et al., 2005; Bellentani, Saccoccio, Costa, Tiribelli,
Manenti, Sodde, et al., 1997; Stickel & Hampe, 2012). Alcohol also un-
covers the liver disease risk conferred by the PNPLA3 variant. A study
in a cohort of Hispanics from Mexico City showed that the 148M allele
is associatedwith an increased risk of developing alcoholic liver disease
and cirrhosis (Tian, Stokowski, Kershenobich, Ballinger, & Hinds, 2010).
This association has been conﬁrmed in Caucasians (Burza, Molinaro,
Attilia, Rotondo, Attilia, Ceccanti, et al., 2013; Seth, Daly, Haber, & Day,
2010; Stickel, Buch, Lau, Zu Schwabedissen, Berg, Ridinger, et al.,
2011; Trépo, Gustot, Degré, Lemmers, Verset, Demetter, et al., 2011).
PNPLA3 148M allele carriers with alcoholic cirrhosis also show an in-
creased risk of developing HCC (Guyot, Sutton, Rufat, Laguillier,
Mansouri, Moreau, et al., 2013; Nischalke, Berger, Luda, Berg, Müller,
Grünhage, et al., 2011; Valenti, Dongiovanni, Ginanni Corradini, Burza,
& Romeo, 2013), which was recently conﬁrmed by a meta-analysis in-
cluding a total of 1374 individuals with cirrhosis caused by excessive al-
cohol intake (Trépo, Nahon, Bontempi, Valenti, Falleti, Nischalke, et al.,
accepted for publication). In this meta-analysis, the risk of developing
HCC was increased over two fold for each PNPLA3 148M allele.
Interestingly, age of onset of the alcohol abuse also seems to change
the risk conferred by the PNPLA3 148Mmutation.We recently studied a
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PNPLA3 148M allele was associated with a three-fold increased risk
for alcoholic cirrhosis in subjects who started the harmful alcohol con-
sumption before age 24 compared to those who started after age 24
(Burza et al., 2013).
Moreover in subjects with chronic hepatitis C, the 148M variant ex-
erts a different effect on the liver according to the alcoholic behavior.
Speciﬁcally research in Caucasians has shown that the PNPLA3 I148M
variant inﬂuences steatosis susceptibility in individuals with chronic
hepatitis C who drink less than 30 g alcohol/day but not in at-risk
drinkers (N30 g alcohol/day); however, the PNPLA3 variant associates
with cirrhosis risk in both groups (Müller, Buch, Berg, Hampe, &
Stickel, 2011; Valenti, Colombo, Fargion, et al., 2011).
In conclusion, excessive alcohol intake is a harmful condition for the
liver that should be discouraged in general and especially in individuals
carrying the PNPLA3 148M allele.
4. Nutrients
4.1. Macronutrients
Excessive intake of carbohydrates, and in particular simple sugars
(e.g. fructose), contributes to fat accumulation in the hepatocytes
(Ouyang et al., 2008). In fact, simple sugars are an ideal substrate for
the synthesis of short-chain fatty acids, a process known as de novo li-
pogenesis (Acheson, Flatt, & Jéquier, 1982). Several studies have
shown evidence of an interaction between the PNPLA3 I148M variant
and carbohydrate intake in determining liver fat accumulation. In a co-
hort of 153 Hispanic children, those homozygous for the PNPLA3 148M
allele showed a positive correlation between carbohydrate intake and
hepatic fat fraction measured by magnetic resonance, while there was
no association in carriers of the PNPLA3 148I wild-type allele (Davis,
Lê, Walker, Vikman, Spruijt-Metz, Weigensberg, et al., 2010). In an in-
terventional study in which 16 Caucasian adults (7 wild-type and 9 ho-
mozygous for the PNPLA3 148M allele) received a high-carbohydrate
diet for 3 weeks, thewild-type individuals showed an expected positive
correlation between lipogenic index (measured bypalmitic acid/linoleic
acid ratio in plasma very low-density lipoproteins) and liver fat content.
However, such a correlationwas not present in individuals homozygous
for the 148M allele, suggesting that the PNPLA3 I148M variant induces
hepatic retention of the de novo synthesized triglycerides
(Sevastianova, Santos, Kotronen, Hakkarainen, Makkonen, Silander,
et al., 2012). Several studies have shown that the PNPLA3 I148Mvariant
indeed affects hepatic very low-density lipoprotein secretion and con-
sequently plasma triglyceride levels (Krarup, Grarup, Banasik,
Friedrichsen, Færch, Sandholt, et al., 2012; Krawczyk, Gruenhage,
Mahler, Tirziu, Acalovschi & Lammert, 2011; Palmer et al., 2012;
Pirazzi, Adiels, Burza, Mancina, Levin, Ståhlman, et al., 2012). Taken to-
gether, these data indicate the presence of an interaction between car-
bohydrate intake and the PNPLA3 I148M variant on liver fat retention.
Fatty acids are present in the fatty liver as the side chains esterifying
the glycerol backbone in triglycerides. Fatty acids are classiﬁed as satu-
rated, mono-unsaturated and poly-unsaturated, based on the presence
and the number of double bonds in their carbon chain. Moreover, the
last carbon atom involved in double bonds represents a marker for the
current fatty acid classiﬁcation (e.g., if the last carbon involved in a dou-
ble bond is the third last of the chain, the fatty acid will be an ω-3)
(Kalish, Fallon, & Puder, 2012). In a recent study, fatty acid composition
of circulating triglycerides was measured in 372 Finnish individuals ge-
notyped for the PNPLA3 I148M variant. Carriers of the PNPLA3 148Mal-
lele showed reduced amounts of oleic acid (18:1 ω-6, the best PNPLA3
substrate in vitro (Huang, Cohen, & Hobbs, 2011)) compared to wild-
type individuals (Hyysalo, Gopalacharyulu, Bian, Hyötyläinen,
Leivonen, Jaser, et al., 2014). In another study in Italian children, treat-
ment efﬁcacy of hepatic steatosis using docosahexaenoic acid (22:6 ω-
3) was affected by the PNPLA3 I148M genotype. Notably, the presenceof the PNPLA3 148M allele worsened the treatment response (Nobili,
Bedogni, Donati, Alisi, & Valenti, 2013). Interestingly, in an independent
pediatric cohort,ω-6/ω-3 fatty acid intake ratio was positively correlat-
ed with liver fat content only in individuals homozygous for the 148M
allele (Santoro, Savoye, Kim, Marotto, Shaw, Pierpont, et al., 2012).
These results indicate that the PNPLA3 148M variant interacts with un-
saturated fatty acids in determining liver fat retention.
4.2. Micronutrients
Iron is a micronutrient with a major role in hematopoiesis (Chung,
Chen, & Paw, 2012). However, iron overload is harmful for the liver. He-
reditary hemochromatosis is a genetic disease characterized byprogres-
sive accumulation of ironmainly in the liver leading to liver ﬁbrosis and
cirrhosis (Pietrangelo, 2010). Although the genetic determinant of he-
mochromatosis is well established, the individual progression of the
liver damage is extremely variable. We examined a cohort of 174 sub-
jects affected by hereditary hemochromatosis and showed that the
PNPLA3 I148M variant is associated with steatosis and severity of ﬁbro-
sis also in this genetic disorder (Valenti, Maggioni, Piperno, Rametta,
Pelucchi, Mariani, et al., 2012). These results show that a common ge-
netic variant may explain the phenotypic variability in the context of a
monogenic disorder.
5. PNPLA3 protein function: a short overview
PNPLA3 function and the effect of the I148M substitution are not yet
completely understood. Puriﬁed PNPLA3 protein has been shown to
have both hydrolase and lysophosphatidic acid transacetylase activities,
with the hydrolase activity predominating (Huang et al., 2011; Kumari,
Schoiswohl, Chitraju, Paar, Cornaciu, Rangrez, et al., 2012; Pingitore,
Pirazzi, Mancina, Motta, Indiveri, Pujia, et al., 2013). The 148Mmutation
has been associated with a loss of function of hydrolase activity (Huang
et al., 2011; Pingitore et al., 2013) and a gain of function of
lysophosphatidic acid transacetylase activity (Kumari et al., 2012). Con-
sistent with a hydrolase activity hypothesis, a relative reduction in he-
patic very low-density lipoprotein secretion with the 148M mutation
has been shown in in vitro studies and in humans (Pirazzi et al.,
2012). Furthermore, in a transgenic mouse model, PNPLA3 148M over-
expression induced increased formation of fatty acids and triglycerides,
impaired hydrolysis of triglycerides, and depletion of long-chain poly-
unsaturated fatty acids (Li, Huang, Karaman, Ivanova, Brown, Roddy,
et al., 2012). On the other hand, wild-type PNPLA3 was also found to
have lysophosphatidic acid transacetylase activity and the 148Mmuta-
tion was found to be a gain of function of the lipogenic activity
(Basantani, Sitnick, Cai, Brenner, Gardner, Li, et al., 2011). In agreement,
rats on a high-fat diet treated with pnpla3 antisense oligonucleotides
showed decreased fatty acid esteriﬁcation into hepatic triglycerides
and reduced insulin resistance (Kumashiro, Yoshimura, Cantley,
Majumdar, Guebre-Egziabher, Kursawe, et al., 2013). In a recent study
of obese adolescents with hepatic steatosis, the I148M variant has
been shown to modulate the association between oxidized metabolites
derived from linoleic acid and cytokeratin 18 fragment, a robust bio-
marker of liver injury (Santoro, Caprio, Giannini, Kim, Kursawe,
Pierpont, et al., 2014). However, further studies are needed to fully un-
derstand the molecular genetics of the PNPLA3 protein.
6. Conclusions
The interaction between the PNPLA3 I148M variant and excessive
intake of food, alcohol or speciﬁc nutrients reveals that the effect of
the stimuli determining changes in liver fat is enhanced in carriers of
the PNPLA3 148M allele. Future studies are warranted to understand
the complex interplay between the whole genome variability and
nutrients.
242 C. Maglio et al. / Food Research International 63 (2014) 239–243In conclusion, the PNPLA3 I148M variant interacts with awide range
of nutrients in determining chronic liver disease. In a future perspective,
this may possibly lead to a speciﬁc genetic-tailored diet to reduce fatty
liver.
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